Article Text

Download PDFPDF
EP746 Predictive factors for chemotherapy-induced nausea in patients with gynecological cancer
  1. VE Di Mattei1,2,
  2. P Taranto2,
  3. M Mazzetti2,
  4. L Carnelli2,3,
  5. M Bernardi4,
  6. PMV Rancoita1,
  7. M Petrone2,
  8. S De Bastiani2,
  9. A Bergamini2,
  10. F Vasta2,
  11. G Mangili2 and
  12. M Candiani1,2
  1. 1Vita-Salute San Raffaele University
  2. 2San Raffaele Hospital
  3. 3University of Milan Bicocca, Milan
  4. 4University of Parma, Parma, Italy


Introduction/Background Chemotherapy-Induced Nausea (CIN) is a distressing side effect for patients undergoing chemotherapy, which deeply affects their quality of life and everyday activities. Several treatment-related and patient-related factors may be involved in the expression of CIN. This study aims to identify predictive factors for nausea after the first chemotherapy infusion in a sample of women with gynecological cancer.

Methodology One hundred and sixty-five patients (mean age=58.23, SD=13.19) treated for gynecological cancer at the San Raffaele Hospital completed the MASCC Antiemesis Tool (MAT) in order to register the presence of acute (within 24 hours) and delayed (24–72 hours) nausea after the first chemotherapy infusion. Socio-demographic and clinical characteristics that could represent risk factors for nausea were collected with an ad hoc questionnaire designed by the research team. Logistic regression analyses were performed for predicting acute or delayed CIN; significance level was set at 0.05.

Results Sixty-three (38.7%) patients experienced acute nausea after their first chemotherapy infusion; 46% (n=75) of the sample experienced delayed nausea. Neoadjuvant (vs. adjuvant) chemotherapy represents a protective factor for delayed CIN (OR=0.350; p=0.033). Hyperemesis gravidarum and anticipatory nausea both represent risk factors for delayed nausea (OR=2.307, p=0.026; OR=4.316; p=0.004, respectively). No significant association was found with acute nausea.

Conclusion Despite advancements in antiemetic therapy, results show that CIN still represents a common chemotherapy side-effect for women with gynecological cancer. Specific patient-related and treatment-related characteristics seem to influence the onset of delayed nausea after the first chemotherapy infusion. The knowledge of risk factors for CIN could help identify patients who are more vulnerable to this symptom and implement specific psychological and medical interventions in order to promote a better adjustment to the disease and its treatment.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.